In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

Understanding the interplay between T cells and B cells is pivotal to delineating both protective immunity and the pathogenesis of autoimmune diseases. Central to this dynamic are specialised CD4⁺ T ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

Scientists analyzing human and mouse pancreatic lymph nodes (PLNs) and spleens have identified a distinct subset of CD4 memory helper T cells associated with type 1 diabetes (T1D). Reported by ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...